Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:

NCT ID: NCT04854798 Completed - Covid19 Clinical Trials

UNITE Study (UMN-SW) for COVID-19

Start date: April 29, 2021
Phase: N/A
Study type: Interventional

The research objective of the UNITE Study is to assess device feasibility of ultrasound application to the spleen using a small wearable ultrasound system to assess its effect on coronavirus disease 2019 (COVID-19) in a pilot study using an early stage prototype device. Specific Aims: 1. Determine the feasibility of splenic ultrasound with a prototype wearable device in affecting physiological markers in COVID-19 infected patients between an ultrasound group versus a control group for the primary analyses; and 2. Evaluate the potential capabilities of splenic ultrasound with this prototype wearable device in affecting additional outcomes in COVID-19 infected patients in the ultrasound group compared to a control group.

NCT ID: NCT04854785 Active, not recruiting - Covid19 Clinical Trials

Neuroinflammation in COVID-19 and Depression

Start date: June 14, 2021
Phase:
Study type: Observational

The purpose of this study is to use state of the art brain imaging technology to investigate neuroinflammation in participants with depression after the respiratory symptoms of coronavirus disease 2019 (COVID-19) have passed.

NCT ID: NCT04854772 Completed - Clinical trials for COVID-19 Long Haul Syndrome

Mind Body Intervention for COVID-19 Long Haul Syndrome

Start date: May 15, 2021
Phase: N/A
Study type: Interventional

The present study is a feasibility study in which we will determine if a mind-body program that we have previously developed for chronic back pain can improve the multiple somatic complaints associated with the COVID Long Haul Syndrome.

NCT ID: NCT04854759 Recruiting - COVID-19 Clinical Trials

The Use of Amantadine in the Prevention of Progression and Treatment of COVID-19 Symptoms

COV-PREVENT
Start date: March 15, 2021
Phase: Phase 3
Study type: Interventional

The use of amantadine in the prevention of progression and treatment of COVID-19 symptoms in patients infected with the SARS-CoV-2 virus. Multicenter randomized, double-blind, placebo-controlled, non-commercial clinical trial

NCT ID: NCT04854486 Withdrawn - Covid19 Clinical Trials

Impact of GSE and Xylitol (Xlear) on COVID-19 Symptoms and Time to PCR Negativisation in COVID-19 Patients

Start date: December 16, 2021
Phase: Phase 3
Study type: Interventional

This clinical trial aims to ascertain the impact of GSE and Xylitol (XLEAR) in decreasing the time of negativisation in PCR testing in patients with COVID-19.

NCT ID: NCT04854408 Completed - Covid19 Clinical Trials

Evaluation of the Effect of Coronavac Vaccine (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2 Vaccine) on Healthcare Workers' Menstrual Patterns

Start date: March 18, 2021
Phase:
Study type: Observational

Coronavac, one of the vaccines developed within the scope of combating the COVID-19 pandemic that has surrounded the world for a year, started to be applied in the first healthcare workers in our country. In this important step taken to end the pandemic, information on vaccines is still limited. Most vaccines, including the Coronavac vaccine, are applied with approval for emergency use before phase 3 studies are fully completed. While investigating the effect of the vaccine on the virus, possible side effects should also be considered. In this context, it is not known whether the vaccine has an effect on the menstrual cycle, especially of women of reproductive age. Our primary aim in our study is to evaluate the effect of the vaccine on the menstrual cycle and if the vaccine has any effect on the menstrual cycle, what kind of changes this effect causes.

NCT ID: NCT04853979 Completed - Clinical trials for Hypoxemic Respiratory Failure

Awake Prone Positioning in COVID-19 Suspects With Hypoxemic Respiratory Failure

Start date: May 16, 2021
Phase: N/A
Study type: Interventional

The investigator hypothesis is that early implementation of early, awake prone position for patients with COVID-19 pneumonia requiring oxygen therapy will reduce the need for escalation of respiratory support. Escalation of respiratory support is defined as the need for respiratory support with HFNO, NIV or IV.

NCT ID: NCT04853966 Completed - Covid19 Clinical Trials

The Effects of Physical Activity Tele-Counseling Intervention in Post-COVID-19 Conditions

Start date: April 17, 2021
Phase: N/A
Study type: Interventional

It has been found that physical activity recommendations with telerehabilitation in different disease groups improve the functional capacity, physical activities and mental health of the patients as much as the supervised exercise programs. However, there are no studies in the literature that provide online physical activity counseling in COVID-19 patients, and evaluate the effect of physical activity counseling on physical activity level, quality of life, physical performance, fatigue, kinesophobia, pain, dyspnea, mental health and behavior change levels. For this reason, this study aimed to evaluate the effect of online physical activity counseling on physical activity level, quality of life, physical performance, fatigue, kinesophobia, pain, dyspnea, mental health and behavior change level in COVID-19 patients.

NCT ID: NCT04853940 Completed - Covid19 Clinical Trials

Respiratory Muscle Function, Dyspnea, Exercise Capacity and Quality of Life in Severe COVID19 Patients

Start date: January 1, 2021
Phase:
Study type: Observational

Further knowledge regarding sequelae in severe COVID-19 patients who have required ICU admission for invasive mechanical ventilation is still needed. Available evidence suggests ongoing respiratory impairment and impact in quality of life.

NCT ID: NCT04853927 Withdrawn - Covid19 Clinical Trials

Proxalutamide Treatment for COVID-19 Patients in Intensive Care Unit

Start date: February 8, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of Proxalutamide as a treatment for COVID-19 patients in the intensive care unit